STOCKS TELEGRAPH

Tag: 9 Meters Biopharma Inc.

  • Why The NMTR Stock Fell Afterhours?

    Why The NMTR Stock Fell Afterhours?

    At last check in after-hours trading, shares of clinical-stage company focused on rare and unmet needs in gastroenterology  9 Meters Biopharma Inc. (NMTR) were down -3.23% at $1.20. Last session, 9 Meters closed at $1.24, up 20.39% or $0.21. During regular trading, the share price of NMTR fluctuated between $1.03 and $1.42.

    There were 43.89 million shares of NMTR stock exchanged, more than the daily volume of 5.11 million for the past 50 days and higher than the volume for the year to date. NMTR stock has fallen 101.36% in the past 12 months and has risen 12.73% in the last week. Over the past three months, NMTR shares have increased by 4.20%, and the stock has dropped by -9.49% during the last six months.

    NMTR stock rose during the regular session on news that it will participate in a biotech conference but has lost ground after hours.

    NMTR will participate in which event?

    9 Meters Biopharma is a gastroenterology company focused on rare and unmet needs. NMTR is developing vurolenatide, an orphan disease medicine, in a Phase 2 clinical trial for short bowel syndrome (SBS). Larazotide, another tight junction regulator, is also being evaluated by NMTR to improve symptoms of celiac disease.

    NMTR CEO John Temperato will participate in a virtual fireside chat at a health event, announced 9 Meters Biopharma.

    The NMTR CEO will take part in the William Blair Biotech Focus Conference on July 14-15, 2021. Investors are invited to join NMTR’s webcast live. John Temperato, Chief Executive Officer of 9 Meters Biopharma, will present at the William Blair Biotech Focus Conference on Thursday, July 15, 2021 at 12:00 to 2:45 p.m. Eastern Time.

    The presentation will be webcast live and may be accessed on the Investors page of the company’s website at https://wsw.com/webcast/blair59/nmtr/1964248, where a replay of the presentation will also be available for a 30-day period.

    Moreover, at the conclusion of the annual Russell US Index reconstitution, 9 Meters Biopharma was added to the Russell 3000 Index, a broad-market index, and the Russell 2000 Index, a small-cap index. As of the opening of the US equity markets on Monday June 28, 2021, these updated Indexes are in effect.

    The Russell indexes represent the 4,000 biggest US stocks based on their total market capitalization as of May 7, 2021. FTSE Russell determines membership for its Russell indexes primarily through objective rankings and criteria that are associated with market capitalization.

    What its addition to Russell means for NMTR?

    NMTR’s perseverance and accomplishments, including adding 9 Meters to the Russell Indexes, are indicative of its efforts to become a treatment leader in rare and unmet gastrointestinal disorders. By including 9 Meters Biopharma (NMTR) in the Russell Indexes, the company will raise its visibility when it is nearing several key milestones.

  • What Is Motivating The NMTR Stock Surge Premarket?

    What Is Motivating The NMTR Stock Surge Premarket?

    In premarket trading on Tuesday, 9 Meters Biopharma Inc. (NMTR) shares were up 3.51% at $1.18. At the end of last trading session, 9 Meters stock closed at $1.14, down 5.0%. A trading volume of 13.59 million shares was recorded by NMTR stock in the last trading session, much higher than the average daily volume of 4.2 million shares for the previous 50 days.

    In the past five days, NMTR’s stock has retreated -18.57%. Over the past month, the stock has fallen -10.24%. In the last three months, the price of NMTR stock has dropped by 13.64%, but has gained 32.71 percent so far this year. After joining the Russell index last session, NMTR stock has been rising.

    Has Russell index’s inclusion impacted NMTR?

    9 Meters Biopharma focuses on rare and unmet gastroenterology needs. NMTR will enroll vurolenatide, a proprietary long-acting GLP-1 agonist, in a Phase 2 clinical trial for short bowel syndrome (SBS). SBS is NMTR’s focal point due to its rarity and orphan status, as well as its Phase 3 tight junction regulator, which is being evaluated for signs and symptoms of non-responsive celiac disease.

    At the conclusion of the Russell US Indexes annual reconstitution, 9 Meters joined the Russell 3000 Index and the Russell 2000 Index for broad-market and small-cap companies, respectively.

    • On June 28, 2021, after the opening of the US equities markets, these updated indices took effect.
    • The Russell indexes are reconstituted annually and contain 4,000 of the largest US stocks as of May 7, 2021, ranked by market capitalization.
    • NMTR’s achievement of adding 9 Meters to this Russell Index is an indication of both the perseverance and achievement of the team as it continues to work towards becoming the treatment leader for rare, unmet gastroenterology disorders.
    • As NMTR gains momentum towards several milestones, inclusion in the Russell Indexes will increase its visibility among the international investment community.

    NMTR stepping towards its goals:

    9 Meters Biopharma (NMTR) recently initiated its Phase 2 trial of vurolenatide, a proprietary long-acting glucagon-like peptide-1 (GLP-1) agonist in adults with SBS. 9 Meters Biopharma is launching a Phase 2 trial of vurolenatide, which represents an important accomplishment for not only the company, but also for patients and families suffering from the devastating effects of SBS, including chronic diarrhea. As a result, NMTR may be a step closer to having longer-acting, more rapid-onset therapy and with a lower safety profile than any currently available therapy, potentially for the benefit of patients.

  • Pre-Market Cues: 45 Stocks Roaring for Change On November 16th

    Pre-Market Cues: 45 Stocks Roaring for Change On November 16th

    CBAK Energy Technology Inc. (CBAT) stock soared 51.22% to $9.3 in pre-market trading.
    Asia Pacific Wire & Cable Corporation Limited (NASDAQ: APWC) shares are trading up 9.74% at $2.14 at the time of writing. The company’s 52-week range was noted as $0.89 to $2.69.
    Electra Meccanica Vehicles Corp. (SOLO) grew over 8.9% at $6.85 in pre-market trading today following analyst’s prediction that electric vehicles will overtake the global automotive sector in the near future.
    CPS Technologies Corporation (CPSH), an Electronic Components company, dropped about -8.72% at $1.57 in pre-market trading Monday.
    HighPoint Resources Corporation (HPR) stock moved up 77.39 percent to $6.67 in the pre-market trading after the news that Bonanza Creek Energy, Inc. BCEI and HighPoint Resources Corporation HPR have agreed on a merger worth $376 million.
    Navidea Biopharmaceuticals Inc. (NAVB) lost over -5.8% at $2.6 in pre-market trading Monday 16 November 2020 after the company announced its financial results for the third quarter and year-to-date 2020.
    Hall of Fame Resort & Entertainment Company (HOFV) is down more than -11.65% at $2.2 in pre-market hours Monday 16 November 2020 as the company and the NFL alumni association offered updates on the success of the inaugural NFL alumni academy. The stock had jumped over 22.06% to $2.49 in the last trading session.
    Before the trading started on 16 November 2020, GreenPower Motor Company Inc. (GP) is up 6.98% to reach $13.48 after the company posted its 2nd quarter financial results for 2021. It has been trading in a 52-week range of $0.82 to $23.45.
    Zomedica Pharmaceuticals Corp. (ZOM) stock plunged -7.07% to $0.088 in the pre-market trading as the plans to initiate commercialization on 30 March 2021 of its TRUFORMATM point-of-care diagnostic platform revealed.
    Polar Power Inc. (NASDAQ: POLA) shares are trading up 7.81% at $3.59 at the time of writing. Company’s 52-week range was noted as $0.95 to $6.56.
    Sino-Global Shipping America Ltd. (SINO) tumbled over -2.92% at $2.66 in pre-market trading today.
    Pinduoduo Inc. (PDD), an Internet Retail company, dropped about -1.78% at $148.59 in pre-market trading Monday as the firm unveils its Q3 results.
    Tellurian Inc. (TELL) stock moved down -4.51 percent to $0.9644 in the pre-market trading as the news appeared that the company is pondering new Asia gas deals After Petronet snub.
    9 Meters Biopharma Inc. (NMTR) lost over -3.58% at $0.8 in pre-market trading Monday 16 November 2020 as the company revealed financial results and business updates.
    Centennial Resource Development Inc. (CDEV) is down more than -2.88% at $0.741 in pre-market hours Monday 16 November 2020 after the company said Sean R. Smith, Chief Executive Officer, is set to attend the Bank of America Securities Global Energy Conference to be held virtually on Thursday. The stock had jumped over 9.14% to $0.76 in the last trading session.
    Before the trading started on 16 November 2020, Genius Brands International Inc. (GNUS) is up 7.38% to reach $1.31, after the company stated that it is set to host a conference call at 10:00 a.m. Eastern Time on Monday, November 16, 2020, to review major initiatives underway and recent developments. The stock has been trading in a 52-week range of $0.05 to $11.73.
    CureVac N.V. (CVAC) stock soared 8.38% to $81.5 in the pre-market trading after the report that the covid-19 vaccine could be a drug industry game-changer. The most recent rating by Jefferies, on September 08, 2020, is a Hold.
    Apple Hospitality REIT Inc. (NYSE: APLE) shares are trading down -2.83% at $12.02 at the time of writing after the company posted 3rd quarter results of operation. The company’s 52-week range was noted as $4.48 to $16.42. Analysts have a consensus price target of $13.
    Transocean Ltd. (RIG) tumbled over -3.7% at $1.04 in pre-market trading today as the company stock soared 53% since the earnings announcement.
    Cinedigm Corp. (CIDM), an Entertainment company, rose about 8.33% at $0.65 in pre-market trading Monday as the company has purchased North American distribution rights to 100 DAYS TO LIVE, a taut psychological thriller set in the world of suicide prevention and mental health.
    Range Resources Corporation (RRC) stock moved down -5.57 percent to $6.78 in pre-market trading as the company recently revealed disappointing earnings.
    UP Fintech Holding Limited (TIGR) gained over 11.9% at $6.02 in pre-market trading Monday 16 November 2020 as the capital market giant revealed that it will announce its Q3 results on November 23, 2020.
    Taubman Centers Inc. (TCO) is up more than 8.11% at $42.68 in pre-market hours Monday 16 November 2020 after the publication report that Simon Property and Taubman have finally agreed on a merger on a well-reduced price of $43.00 per share in cash. The stock had jumped over 5.53% to $39.48 in the last trading session.
    Before the trading started on 16 November 2020, Banco Bilbao Vizcaya Argentaria S.A. (BBVA) is up 15.24% to reach $4.31 after the announcement that PNC Financial Services Group Inc (NYSE: PNC) is set to take over Banco Bilbao Vizcaya Argentaria (BBVA) U.S. business in an $11 billion all-cash deal. The stock has been trading in a 52-week range of $2.49 to $5.80.
    Kandi Technologies Group Inc. (KNDI) stock soared 7.62% to $7.77 in the pre-market trading as the Company announced that It completed a registered direct offering of 9,404,392 shares of its securities at a sales price of $6.38 per share, raising about $60,000,000 in net gross proceeds to the Firm before deducting the selling agent’s fees and other expected offering expenditures incurred by the Company.
    Textainer Group Holdings Limited (NYSE: TGH) shares are trading down -5.5% at $15.65 at the time of writing after the company posted its third-quarter results. The company’s 52-week range was noted as $5.50 to $17.33. Analysts have a consensus price target of $18.
    Gulfport Energy Corporation (GPOR) tumbled over -45.61% at $0.13 in pre-market trading today after the company filed for bankruptcy.
    Akerman Corp. (KERN), a Health Information Services company, dropped about -3.46% at $2.79 in pre-market trading Monday after the company posted its earnings results.
    United States Antimony Corporation (UAMY) stock moved up 4.17 percent to $0.375 in the pre-market trading.
    ADiTx Therapeutics Inc. (ADTX) lost over -2.03% at $1.93 in pre-market trading Monday 16 November 2020 as the company offered the latest business updated as well as its fiscal quarterly report.
    Arbutus Biopharma Corporation (ABUS) is up more than 10.19% at $4.0 in pre-market hours Monday 16 November 2020 after the firm revealed presentation of phase 1a/1b clinical trial results for AB-729 in chronic hepatitis B subjects at the liver meeting digital experience, the American Association for the study of Liver Diseases meeting. The stock had jumped over 2.25% to $3.63 in the last trading session.
    Before the trading started on 16 November 2020, Ideanomics Inc. (IDEX) is up 31.31% to reach $1.3 after the company revealed the final agreement to take over Timios holding corps. It has been trading in a 52-week range of $0.28 to $3.98.
    Pacific Ethanol Inc. (PEIX) stock soared 4.71% to $6.0 in the pre-market trading as the company announced Q3 results. The most recent rating by BWS Financial, on September 22, 2020, is a Buy.
    CEL-SCI Corporation (AMEX: CVM) shares are trading up 10.5% at $14.0 at the time of writing. The company’s 52-week range was noted as $6.35 to $18.00. Analysts have a consensus price target of $18.
    AMC Entertainment Holdings Inc. (AMC) grew over 8.42% at $3.22 in pre-market trading today following news that Cinemark joins AMC in pursuing a shortened movie window.
    Sogou Inc. (SOGO), an Internet Content & Information company, dropped about -3.14% at $8.64 in pre-market trading Monday as the company unveiled its Q3, 2020 results.
    ObsEva SA (OBSV) stock moved up 18.84 percent to $2.46 in the pre-market trading as the company announced the positive topline results of PROLONG, the Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled trial of laropiprant in preterm labor.
    Denison Mines Corp. (DNN) lost over -9.3% at $0.32 in pre-market trading Monday 16 November 2020 after the company announced the establishment of the At-The-Market Program.
    Pyxis Tankers Inc. (PXS) is down more than -25.74% at $0.8763 in pre-market hours Monday 16 November 2020 as the company announced results for its 3rd quarter and year to date. The stock had dropped over 0.00% to $1.18 in the last trading session.
    Before the trading started on 16 November 2020, Qutoutiao Inc. (QTT) is down -2.13% to reach $2.3. It has been trading in a 52-week range of $2.12 to $6.55.
    Uxin Limited (UXIN) stock plunged -3.85% to $1.0 in the pre-market trading after the news that the company’s Net Promoter Score (NPS) increases to 30 during the quarter ended September 30, 2020. The most recent rating by JP Morgan, on October 23, 2019, is at a Neutral.
    VistaGen Therapeutics Inc. (NASDAQ: VTGN) shares are trading down -2.13% at $0.6851 at the time of writing. The company’s 52-week range was noted as $0.29 to $1.15. Analysts have a consensus price target of $6.
    Sypris Solutions Inc. (SYPR), an Auto Parts company, dropped about -3.6% at $1.34 in pre-market trading Monday after the company announced its 3rd quarter earnings results.
    Alterity Therapeutics Limited (ATHE) stock moved up 169.57 percent to $3.1 in the pre-market trading.

  • 20 Trending Stocks In Biotechnology Industry You Should Consider Buying

    20 Trending Stocks In Biotechnology Industry You Should Consider Buying

    Investors are always looking for safe and secure investments and as a strong and profitable industry, the biotechnology industry is considered to be an attractive area of investment. This industry has experienced massive growth in recent years and is continuously adopting new technological advancements to keep pace with the fast-growing market. Biotechnology is a set of tools that uses living organisms to create or change a product, improve plants, trees, or animals, or develop microorganisms for specific uses.

    Modern Biotechnology’s main focus is on medicine. The companies in this sector are involved in the development of new treatments for various complex diseases. Technology has always been at the heart of the biotechnology industry. As the new technologies emerged with the passage of time the efficiency of companies has also improved. Similarly, technological advancements have also changed the clinical trial process.

    There are various other trends that the companies are following. Let see the top 20 companies in the biotechnology industry to get a better view:

    Cassava Sciences Inc. (NASDAQ: SAVA)

    Cassava Sciences Inc. (NASDAQ: SAVA) last closed at $11.47, in a 52-week range of $1.05 to $11.25. Analysts have a consensus price target of $17.00. Cassava Sciences Inc. (SAVA) has earlier announced the results of the Phase 2b study with its drug candidate Sumifilam, in Alzheimer’s disease. The clinical study which has received the funding by the National Institutes of Health (NIH) has shown the improvement in Alzheimer’s disease. Cassava Sciences Inc. (SAVA) market cap has remained high, hitting $242.02 M at the time of writing.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock soar by 10.21% to $16.94. The most recent rating by ROTH Capital, on July 01, 2020, is at a Sell. Inovio Pharmaceuticals Inc. (INO) has revealed that the US Food and Drug Administration (FDA) has informed the company that it has some questions related to the Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA 2000 delivery device to be used in the trial. the company said that it will halt the trial until it clear all the ambiguities of FDA.

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) Shares headed rising, higher as much as 4.84%. The most recent rating by H.C. Wainwright, on July 31, 2020, is at a Buy. Sorrento Therapeutics Inc. (SRNE) has earlier revealed the results of its’ multicenter, open-label, Phase 1b Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for the Treatment of Intractable Cancer Pain at the 14th Annual Pain Therapeutics Summit. The company has reported the encouraging results from its Phase 1b study to evaluate Epidural Resiniferatoxin Injection.

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (NASDAQ: VXRT) rose 7.40% after gaining more than $0.51 on Friday. Pomerantz LLP is investigating claims on behalf of investors of Vaxart, Inc. Vaxart Inc. share price went from a low point around $0.25 to briefly over $17.49 in the past 52 weeks, though shares have since pulled back to $7.40. Vaxart Inc.’s market cap has remained high, hitting $752.43 M at the time of writing.

    Novavax Inc. (NASDAQ: NVAX)

    Novavax Inc. (NASDAQ: NVAX) stock soar by 10.86% to $113.56. The most recent rating by H.C. Wainwright, on August 06, 2020, is at a Buy. Par Sterile Products, LLC (Par Sterile) has entered into a non-exclusive agreement with Novavax, Inc. to provide fill-finish manufacturing services at its plant in Rochester, Michigan for NVX-CoV2373, Novavax’ COVID-19 vaccine candidate.

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) Shares headed falling, lower as much as -3.23%. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy. Onconova Therapeutics Inc. (ONTX) earlier revealed that it has started the Phase 1 clinical trial in China for ON 123300 by its partner, HanX Biopharmaceuticals. Onconova has partnered with HanX Biopharmaceuticals in December 2017 for the development, registration, and commercialization of ON 123300 in China.

    Jaguar Health Inc. (NASDAQ: JAGX)

    Jaguar Health Inc. (NASDAQ: JAGX) last closed at $0.31, in a 52-week range of $0.29 to $1.38. Jaguar Health Inc. (JAGX) earlier revealed itis scheduled to participate in its first “Diarrhea Dialogues” virtual event on October 20 from 3:00 PM. The event, open to the financial and business community, will discuss the importance of supportive care for cancer patients as it relates to chronic lower GI tract distress, specifically with regard to debilitating diarrhea experienced as a result of cancer therapy.

    Zogenix Inc. (NASDAQ: ZGNX)

    Zogenix Inc. (NASDAQ: ZGNX) stock drop by -1.46% to $17.50. The most recent rating by Raymond James, on August 25, 2020, is at an Mkt perform. Zogenix Inc. (ZGNX) has revealed the pricing of its offering of $200,000,000 aggregate principal amount of 2.75% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

    Trevena Inc. (NASDAQ: TRVN)

    Trevena Inc. (NASDAQ: TRVN) Shares headed rising, higher as much as 4.04%. The most recent rating by Guggenheim, on September 14, 2020, is at a Buy. Trevena Inc. (TRVN) has earlier participated in three presentations at the virtual 2020 American College of Clinical Pharmacology (ACCP) Annual Meeting. The meetings have taken place from September 21st to 23rd, 2020.

    VBI Vaccines Inc. (NASDAQ: VBIV)

    VBI Vaccines Inc. (NASDAQ: VBIV) last closed at $3.08, in a 52-week range of $0.47 to $6.93. VBI Vaccines Inc. (VBIV) is scheduled to participate in upcoming presentations including Sci-B-Vac: Results on Ph3 Hep B vaccine, Targeting CMV for the development of effective GBM immunotherapy on September 29 and 30, 2020, respectively. It has today participated in the COVID-19 panel discussion on the topic: What existing treatments and vaccine development platforms show promise to control the rate of infection and spread?

    Brickell Biotech Inc. (NASDAQ: BBI)

    Brickell Biotech Inc. (NASDAQ: BBI) Shares headed rising, higher as much as 3.90%. The most recent rating by Lake Street, on August 28, 2020, is at a Buy. Brickell Biotech Inc. (BBI) has revealed that its Japanese development partner, Kaken Pharmaceutical Co., Ltd. has received approval to manufacture and market sofpironium bromide gel, 5% under the brand name ECCLOCK in Japan for the treatment of primary axillary (underarm) hyperhidrosis.

    VYNE Therapeutics Inc. (NASDAQ: VYNE)

    VYNE Therapeutics Inc. (NASDAQ: VYNE) Shares headed falling, lower as much as -6.17%. VYNE Therapeutics Inc. (VYNE) has revealed that the Company will host a physician symposium on AMZEEQ and ZILXI™ on Thursday, October 1, 2020. VYNE market cap has remained high, hitting $271.70-M at the time of writing.

    Acorda Therapeutics Inc. (NASDAQ: ACOR)

    Acorda Therapeutics Inc. (NASDAQ: ACOR) shares were trading up 30.13% at $0.62 at the time of writing on Friday. Acorda Therapeutics Inc. (NASDAQ: ACOR) share price went from a low point around $0.42 to briefly over $3.27 in the past 52 weeks, though shares have since pulled back to $0.62. ACOR market cap has remained high, hitting $22.70M at the time of writing, giving it a price-to-sales ratio of more than 0. If we look at the recent analyst rating ACOR, H.C. Wainwright downgraded coverage on ACOR shares with a Neutral rating.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) last closed at $69.47, in a 52-week range of $13.53 to $95.21. Analysts have a consensus price target of $91.90. Moderna Inc. (MRNA) has moved up 413.45% from its 52-weeks low and moved down -327.03% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 17.30. This company’s market capitalization has remained high, hitting $25.72 billion at the time of writing.

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) rose 7.77% after gaining more than $0.15 on Friday. iBio Inc. (IBIO) share price went from a low point around $0.05 to briefly over $7.45 in the past 52 weeks, though shares have since pulled back to $2.08. iBio Inc. has moved up 4060.00% from its 52-weeks low and moved down -72.08% from its 52-weeks high.  IBIO market cap has remained high, hitting $336.61 M at the time of writing.

    Akebia Therapeutics Inc. (NASDAQ: AKBA)

    Akebia Therapeutics Inc. (NASDAQ: AKBA) rose 0.81% after gaining more than $0.02 on Friday.  In the past 52-weeks of trading, this company’s stock has fluctuated between the low of $2.34 and a high of $13.71. It has moved up 5.98% from its 52-weeks low and moved down -8191% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 2.30. This company’s market capitalization has remained high, hitting $347.50 million at the time of writing.

    Vaccinex Inc. (NASDAQ: VCNX)

    Vaccinex Inc. (NASDAQ: VCNX) stock drop by -1.10% to $1.79. The most recent rating by BTIG Research, on September 23, 2020, is at a Neutral. Vaccinex Inc. (VCNX) share price went from a low point around $1.70 to briefly over $12.23 in the past 52 weeks, though shares have since pulled back to $1.79. VCNX has moved up 5.29% from its 52-weeks low and moved down -85.36% from its 52-weeks high.  VCNX market cap has remained high, hitting $36.19M at the time of writing.

    Ocugen Inc. (NASDAQ: OCGN)

    Ocugen Inc. (NASDAQ: OCGN) rose 2.29% after gaining more than $0.0 on Friday. In the past 52-weeks of trading, this company’s stock has fluctuated between the low of $0.17 and a high of $16.80. It has moved up 78.53% from its 52-weeks low and moved down -98.19% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 3.30. This company’s market capitalization has remained high, hitting $40.03 million at the time of writing.

    9 Meters Biopharma Inc. (NASDAQ: NMTR)

    9 Meters Biopharma Inc. (NMTR) last closed at $0.76, in a 52-week range of $0.37 to $1.22. 9 Meters Biopharma Inc. (NMTR) has moved up 106.59% from its 52-weeks low and moved down -37.33% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 1.30. This company’s market capitalization has remained high, hitting $101.25 million at the time of writing.

    Clovis Oncology Inc. (NASDAQ: CLVS)

    Clovis Oncology Inc. (NASDAQ: CLVS) stock soar by 3.25% to $5.88. The most recent rating by H.C. Wainwright, on May 18, 2020, is at a Buy. Clovis Oncology Inc. (CLVS) share price went from a low point around $2.93 to briefly over $17.37 in the past 52 weeks, though shares have since pulled back to $5.88. CLVS has moved up 100.68% from its 52-weeks low and moved down -66.15% from its 52-weeks high.  CLVS market cap has remained high, hitting $502.33M at the time of writing.

     

  • 20 Trending Stocks In Biotechnology Industry That Need Your Attention

    20 Trending Stocks In Biotechnology Industry That Need Your Attention

    Biotechnology is considered to be the backbone of many industrial sectors and it makes a significant contribution to the well being of society. Every single day we saw changes in every sector as we experience advancements of knowledge and the new technological breakthroughs.  One of the industries that constantly change is the biotechnology industry.

    2020 is the year of continuous development and improvement in drug research. This industry is the leading rapidly growing sector of the economy. There are various trends in the biotechnology industry that the world should expect in the coming years such as the production of personalized medicines thanks to the advancement in genetics and continuous development and improvement in drug research.

    Let’s take a quick look at the 20 leading companies which are following new trends in the biotechnology sector:

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (NASDAQ: VXRT) shares were trading up 46.79% at $7.78 at the time of writing on Monday. Vaxart Inc. (NASDAQ: VXRT) share price went from a low point around $0.25 to briefly over $17.49 in the past 52 weeks, though shares have since pulled back to $7.78. VXRT market cap has remained high, hitting $766.25M at the time of writing, giving it a price-to-sales ratio of more than 90.

    Vaxart Inc. has revealed that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for its Phase 1 clinical trial evaluating its oral COVID-19 vaccine candidate. Vaxart Inc. also gave an update on its COVID-19 program.

    Cassava Sciences Inc. (NASDAQ: SAVA)

    Cassava Sciences Inc. (NASDAQ: SAVA) last closed at $7.75, in a 52-week range of $1.05 to $10.95. Cassava Sciences has announced the final results of a Phase 2bclinical study of Sumifilam in patients with Alzheimer’s Disease. Sumifilam is the first of a new class of drug compounds that bind to a protein called Filamin A. Cassava Sciences Inc. (SAVA) has earlier held a conference call on September 14.  Cassava Sciences Inc.’s market cap has remained high, hitting $182.51 million at the time of writing.

    Immunomedics Inc. (IMMU)

    Immunomedics Inc. (IMMU) stock soar by 97.99% to $83.65. The most recent rating by Barclays, on May 05, 2020, is at an Overweight. Gilead Sciences Inc. (NASDAQ: GILD) has earlier announced that it has decided to buy biotech company Immunomedics Inc for $21 billion. This decision will strengthen its cancer portfolio by gaining access to a promising drug.  Immunomedics Inc. (IMMU) has a total market capitalization of $19.19 billion.

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares headed rising, higher as much as 17.88%. The most recent rating by H.C. Wainwright, on July 31, 2020, is at a Buy. Sorrento Therapeutics Inc. (NASDAQ: SRNE) has earlier disclosed that it has signed an exclusive license agreement with Mayo Clinic for an antibody-drug-nanoparticle albumin-bound (nab) immune complexes (ADNICs) platform targeting many types of human diseases including various solid and liquid tumors. Sorrento Therapeutics Inc. has a market cap of $1.86 billion.

    Novan Inc. (NASDAQ: NOVN)

    Novan Inc. (NASDAQ: NOVN) rose 13.00% after gaining more than $0.06 on Monday. Novan Provides Pipeline and Priority Development Programs Update. Novan Inc. (NOVN) gave a pipeline and priority development programs update. Novan Inc.’s share price went from a low point around $0.22 to briefly over $3.72 in the past 52 weeks, though shares have since pulled back to $0.53. Novan Inc.’s market cap has remained high, hitting $82.02 million at the time of writing.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock soar by 12.30% to $11.32. The most recent rating by ROTH Capital, on July 01, 2020, is at a Sell. Inovio Pharmaceuticals Inc. (INO) has earlier signed a manufacturing agreement with Thermo Fisher Scientific. Thermo Fisher Scientific has signed a letter of intent to manufacture INOVIO’s DNA COVID-19 vaccine candidate INO-4800.

    Evofem Biosciences Inc. (NASDAQ: EVFM)

    Evofem Biosciences Inc. (NASDAQ: EVFM) Shares headed rising, higher as much as 11.90% after Evofem Biosciences to present data at the 2020 STD prevention Virtual Conference from Phase 2b Trial of EVO100 for prevention of Chlamydia and Gonorrhea in Women. The most recent rating by Morgan Stanley, on August 20, 2020, is at an Equal-weight.

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) rose 9.28% after gaining more than $0.18 on Monday. iBio Inc. (AMEX: IBIO) has earlier disclosed that it has selected IBIO-201, its LicKM-ubunit vaccine, as its leading candidate for the prevention of SARS-CoV-2 infection. iBio revealed earlier the preclinical immunization studies with IBIO-200 and IBIO-201, combined with select adjuvants from the Infectious Disease Research Institute, induced anti-SARS-CoV-2 antibodies.  iBio Inc has a market capitalization of $379.31 million.

    Clovis Oncology Inc. (CLVS)

    Clovis Oncology Inc. (CLVS) last closed at $7.00, in a 52-week range of $2.93 to $17.37. CLVS has traded up 138.91% from its 52-weeks low and traded down -59.70% from its 52-weeks high. Analysts have a consensus price target of $9.00. Clovis Oncology Inc. (CLVS) has earlier announced Oral Plenary Session Presentation at the International Gynecologic Cancer Society (IGCS)digital annual global meeting.

    Heat Biologics Inc. (NASDAQ: HTBX)

    Heat Biologics Inc. (NASDAQ: HTBX) stock soar by 1.82% to $1.12. The most recent rating by ROTH Capital, on June 20, 2016, is at a Buy. Heat Biologics Inc. (HTBX) has earlier participated in a virtual panel, entitled, “New Approaches to COVID-19: Hidden Breakthroughs,” being held on Thursday, September 10. Heat Biologics has also issued a key patent on combination platform therapy. Heat Biologics Inc. has a total market capitalization of $170.96 million.

    VBI Vaccines Inc. (NASDAQ: VBIV)

    VBI Vaccines Inc. (NASDAQ: VBIV) shares headed rising, higher as much as 12.82% after VBI Vaccines to present additional biomarker data from VBI-1901 Phase 1/2a Study in Recurrent GBM in an E-Poster at ESMO Virtual Congress 2020. The most recent rating by Raymond James, on August 27, 2020, is at a Strong buy. Its market capitalization has remained high, hitting $813.82 million.

    Dynavax Technologies Corporation (NASDAQ: DVAX)

    Dynavax Technologies Corporation (NASDAQ: DVAX) rose 13.37% after gaining more than $0.67 on Monday. Valneva and Dynavax have announced a Commercial supply agreement for Inactivated, adjuvanted COVID-19 vaccine. This is a commercial partnership for the supply of Dynavax’s CpG 1018 adjuvant for use in Valneva’s SARS-CoV-2 vaccine candidate, VLA2001. Dynavax will supply CpG 1018 to produce up to 100 million doses of vaccine in 2021. Valneva has the opportunity to purchase up to an additional 90 million doses through 2025.

    Zosano Pharma Corporation (NASDAQ: ZSAN)

    Zosano Pharma Corporation (NASDAQ: ZSAN) last closed at $1.72, in a 52-week range of $0.41 to $2.45. Zosano Pharma Corporation (ZSAN) is scheduled to participate in a Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020. At the conference, Zosano Pharma Corporation will present the company overview. Zosano Pharma Corporation has a total market capitalization of $138.86 million at the time of writing.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) stock soar by 7.30% to $63.67. The most recent rating by SVB Leerink, on September 08, 2020, is at an Underperform. Moderna Inc. (MRNA) has earlier named Michael Millette as Managing Director, Canada effective immediately. Michael Millette has joined Moderna Inc in August 2020 as Vice President. Moderna Inc has a total market cap of $24.37 billion at the time of writing.

    9 Meters Biopharma Inc. (NASDAQ: NMTR)

    9 Meters Biopharma Inc. (NASDAQ: NMTR) Shares headed rising, higher as much as 12.61%. 9 Meters Biopharma Inc. (NASDAQ: NMTR) is scheduled to participate in the upcoming two conferences in September including H.C. Wainwright: 22nd Annual Global Investment Conference and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. These two conferences are scheduled to take place on September 15 and September 23, respectively.

    Ampio Pharmaceuticals Inc. (AMEX: AMPE)

    Ampio Pharmaceuticals Inc. (AMEX: AMPE) rose 10.80% after gaining more than $0.08 on Monday. Ampio Pharmaceuticals Inc. (AMPE) has revealed positive results in the early trial for intravenous Ampion treatment for COVID-19 patients on September 9, 2020. The Phase I trial was continued in the supervision of Michael Roshon, MD, Ph.D., Chief of Staff at Penrose-St. Francis Hospital in Colorado Springs, Colorado.

    Novavax Inc. (NASDAQ: NVAX)

    Novavax Inc. (NASDAQ: NVAX) last closed at $105.80, in a 52-week range of $3.54 to $189.40. Novavax Inc. (NVAX) is scheduled to participate in the upcoming three conferences including Cantor Virtual Global Healthcare Conference, Morgan Stanley Virtual 18th Annual Global Healthcare Conference, and Leerink CyberRx Series: Vaccine Forum on September 15, 16, and 23, respectively. It has earlier participated in Citi 15th Annual BioPharma Virtual Conference, and H.C. Wainwright 22nd Annual Global Investment Conference on September 10, and 14, 2020, respectively.

    Marinus Pharmaceuticals Inc. (NASDAQ: MRNS)

    Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) stock soar by 5.50% to $2.11. The most recent rating by H.C. Wainwright, on July 01, 2020, is at a Buy. Marinus Pharmaceuticals Inc. (MRNS)has disclosed that it has entered into a five-year development contract with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of IV ganaxolone for the treatment of refractory status epilepticus (RSE).

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) Shares headed falling, lower as much as -3.28%. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy. Onconova Therapeutics Inc. (NASDAQ: ONTX) has earlier participated in two virtual events including Marcus Evans Healthcare Investment Webinar on September 10 and H.C. Wainwright 22nd Annual Global Investment Conference onSeptmerb 14. It is scheduled to participate in the 2nd Annual RAS-Targeted Drug Development Conference on September 16, 2020.

    Trevena Inc. (NASDAQ: TRVN)

    Trevena Inc. (NASDAQ: TRVN) last closed at $2.08, in a 52-week range of $0.46 to $3.68. In the past 52-weeks of trading, Trevena Inc. (TRVN) stock fluctuated between the low of $0.46 and a high of $3.68. It has moved up $352.17% from its 52-weeks low and moved down -43.48% from its 52-weeks high. Its market capitalization is $306.38 million at the time of writing.